Fibromyalgia And Mental Health

Introduction — who needs this guide and why it matters

Fibromyalgia and Mental Health are tightly linked, and most people searching want to know whether fibromyalgia causes mood problems, how to get help, and what treatments reliably work.

People with persistent widespread pain, caregivers, primary care clinicians, and mental health professionals need this guide. Global prevalence is estimated at about 2–4% of adults, women represent roughly 80–90% of clinical cases, and clinic samples report mood disorder comorbidity in approximately 40–60% of patients (see PubMed review and JAMA prevalence analyses).

We researched clinical trials, guidelines, and reviews to build concrete takeaways: a rapid screening checklist, a 6‑step treatment priority plan, suggested wording to use with clinicians, and three reliable resource links you can use today.

Early authoritative resources we used: CDC Fibromyalgia, NIH/NINDS, and WHO. We researched randomized trials and cohort data to ensure the recommendations below reflect evidence through 2026.

Where to find things in this guide: mechanisms and brain changes (next), screening tools and prevalence (section on common comorbidities), practical treatment priorities (psychotherapy, meds, exercise), crisis planning, workplace and legal guidance, and research gaps you can act on.

Fibromyalgia and Mental Health: how fibromyalgia affects mood and the brain

How pain rewires mood circuits. Chronic nociceptive input and central sensitization change how the central nervous system processes both pain and emotion. Functional MRI studies show altered connectivity in the default mode network and reduced prefrontal regulation of limbic regions; one fMRI meta‑analysis reported consistent changes in the anterior insula and anterior cingulate cortex with moderate effect sizes (Cohen’s d ~0.5–0.8).

Biological pathways include altered neurotransmitter levels—reduced serotonin and norepinephrine availability, elevated substance P—and HPA‑axis dysregulation with blunted cortisol rhythms in many cohorts. Small cohort studies reported higher serum inflammatory markers (e.g., IL‑6) in subsets of patients, though effect sizes are heterogeneous across studies.

Concrete data points: 1) fMRI studies find altered pain processing in >70% of imaging cohorts; 2) serum marker studies show IL‑6 elevation in ~30–40% of small samples; 3) a systematic review linked HPA‑axis abnormalities to worse fatigue and depressive symptoms.

Bidirectional cycle: pain → poor sleep → worse mood → increased pain sensitivity. Sleep fragmentation alone raises pain sensitivity by measurable amounts: experimental sleep restriction increases heat‑pain sensitivity by ~20–30% in healthy volunteers, and similar mechanisms are seen in fibromyalgia cohorts.

Simple causal diagram:

• Chronic nociception / central sensitization → increased pain perception
• Pain → sleep disruption, activity avoidance, social withdrawal
• Poor sleep & stress → HPA dysregulation, neuroinflammation
• Mood symptoms → catastrophizing → amplified pain

Case vignette: Maria, a 42‑year‑old teacher, developed widespread pain at age after a viral illness. Over five years, pain increased despite analgesics, sleep dropped to 3–4 hours nightly, and she stopped exercising. At she reported low mood, loss of interest, and difficulty concentrating; PHQ‑9 = 14. After combined CBT and graded activity she improved function by 40% and PHQ‑9 fell to at weeks.

We researched randomized and cohort studies that quantify how mood symptoms contribute to disability; several longitudinal studies show depressive symptoms predict 6–12 month functional decline independent of baseline pain intensity. For clinicians: ask about mood and sleep routinely because treating those domains reduces disability more than treating pain alone (multiple trials through report this finding).

Quick answers to common questions:

Does fibromyalgia cause depression? Evidence supports a strong association; fibromyalgia increases risk for depressive disorders but depression is not the sole cause—both share biological drivers and behavioral effects.

Why do fibromyalgia patients have anxiety? Anxiety arises from pain unpredictability, hypervigilance, sleep loss, and shared neurochemical changes (serotonin/norepinephrine imbalance); treating anxiety improves coping and reduces catastrophizing.

Common mental health conditions seen with fibromyalgia

Overview and table (at a glance). Below is a compact table listing the common psychiatric and cognitive comorbidities, prevalence in fibromyalgia cohorts, recommended screening tool, and a first‑line treatment approach.

Table — Condition | Prevalence | Screening tool (cutoff) | First‑line treatment

• Major depressive disorder | 30–60% (clinic samples) | PHQ‑9 (≥10 moderate) | CBT + SNRI (duloxetine) or SSRI
• Generalized anxiety / panic | 20–45% | GAD‑7 (≥10 moderate) | CBT for anxiety ± SSRI/SNRI
• PTSD | 10–25% (varies by trauma exposure) | PCL‑5 (≥33 probable) | Trauma‑focused CBT / EMDR
• Insomnia | 50–80% | PSQI (>5 poor sleep) / 2‑week diary | CBT‑I + sleep hygiene
• Cognitive dysfunction (“fibro fog”) | 40–70% | Trail Making / MOCA subset | Sleep, exercise, cognitive rehab

Specific measurement tools and cutoffs:

• PHQ‑9: 0–4 none, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe. Refer to psychiatry for PHQ‑9 ≥20 or active SI.
• GAD‑7: 0–4 minimal, 5–9 mild, 10–14 moderate, ≥15 severe. For GAD‑7 ≥10, consider CBT or medication.
• PCL‑5: ≥33 suggests probable PTSD; combine with trauma history.
• PSQI: >5 indicates clinically significant sleep disturbance.

We recommend routine screening: screen all patients with fibromyalgia for depression and anxiety at diagnosis and then annually, or sooner if symptoms change—this aligns with clinical guidance from pain and mental health societies and NIH commentary through 2025.

Prevalence evidence: a meta‑analysis reported pooled depression prevalence ~39% in clinic samples; a cohort found anxiety prevalence ~34% among referred patients. See PubMed links for cohort details.

Short clinical definitions:

• Can fibromyalgia cause anxiety? Yes—anxiety frequently coexists and worsens pain coping; treatable with psychotherapy and medication when needed.
• What is fibro fog? A cluster of cognitive complaints—memory, attention, verbal fluency—often fluctuating and partly reversible with sleep and behavioral interventions.

We found that clear screening and stepped care reduces missed comorbidity and shortens time to effective treatment. Next, practical approaches for depression and anxiety follow in the depression and anxiety subsections.

Depression in fibromyalgia (signs, screening, and what to do)

How depression looks in fibromyalgia. Patients commonly report persistent low mood, loss of interest (anhedonia), early morning awakening, appetite change, slowed thinking, and concentration problems that overlap with fatigue and pain. Because symptoms overlap, screening tools are essential.

Screening workflow (step‑by‑step):

1. Administer PHQ‑9 — if score <5, continue routine monitoring; 5–9 offer low‑intensity interventions; ≥10 indicates probable major depression and needs active treatment.< />i>
2. Risk stratify — ask about suicidal ideation (item on PHQ‑9). If SI present with plan or intent, arrange urgent assessment.
3. Optimize sleep and pain — correct reversible contributors (sleep apnea screening, medication side effects).
4. Start psychotherapy ± meds — mild: CBT or behavioral activation; moderate–severe: SNRI (duloxetine) or SSRI and psychotherapy.
5. Follow‑up — schedule 2–4 week check for tolerability and safety; measure PHQ‑9 at each visit.
6. Safety planning — document contacts and coping strategies for any SI.

Treatment evidence and specifics: Duloxetine has FDA approval for fibromyalgia and demonstrates modest benefits for pain and mood; pooled NNTs in trials vary but are often in the 6–10 range for clinically meaningful pain reduction. CBT reduces depressive symptoms and improves function—meta‑analyses through show small‑to‑moderate effect sizes (SMD ~0.3–0.5).

6‑step clinician checklist for a visit (copy/paste):

1. Screen with PHQ‑9 and document score.
2. Risk stratify (ask item 9; if positive, safety plan).
3. Optimize sleep/pain contributors (sleep study referral if apnea suspected).
4. Offer psychotherapy (CBT) and discuss medication options; start SNRI if moderate–severe.
5. Schedule follow‑up in 2–4 weeks; measure PHQ‑9 again.
6. Provide safety resources and involve family/support if needed.

Wording patients can use: “I’ve had low mood for six weeks, I’m sleeping 3–4 hours nightly, and I can’t enjoy hobbies anymore. My PHQ‑9 is 14.” This frames symptom duration, sleep, and function.

Sample referral letter to psychiatry (one paragraph):

Patient: [Name], DOB [xx/xx/xxxx]. Problem: chronic fibromyalgia with PHQ‑9 = [score], ongoing low mood for >8 weeks, sleep 3–4 hours/night, limited response to non‑pharmacologic measures. Request: psychiatric evaluation for antidepressant initiation and psychotherapy linkage. Current meds: [list]. Urgency: non‑urgent but appointment within 2–4 weeks preferred.

We recommend repeating PHQ‑9 at each visit and documenting functional targets (e.g., return to part‑time work or minutes daily walking) to guide treatment decisions.

Anxiety, PTSD, and cognitive symptoms in fibromyalgia

Anxiety presentations. Patients may present with generalized worry, panic attacks, or health anxiety focused on unpredictable pain flares. Prevalence in referred samples ranges 20–45%; higher anxiety correlates with more catastrophizing and poorer function.

PTSD overlap. For patients with prior trauma, PTSD prevalence can be 10–25% depending on population. Trauma‑focused CBT or EMDR show moderate effect sizes for both PTSD and comorbid pain in trials through 2023–2025.

Cognitive complaints (fibro fog). Common cognitive complaints: short‑term memory lapses, slowed processing, word‑finding problems. Objective testing often shows mild deficits in attention and executive function. Use Trail Making A (cutoff times age‑adjusted) and MOCA subtests; if impairment is moderate, consider neuropsychology referral.

Assessment and brief tests:

• Trail Making A/B — sensitive to attention/executive problems.
• MOCA‑5 subset — 5–10 minute screen for executive and memory problems.
• Digit Span or verbal fluency — quick bedside checks.

Treatment and lifestyle adjustments: CBT for anxiety and trauma‑focused therapies for PTSD have the best evidence; for cognitive complaints, prioritize sleep improvement, graded exercise, and cognitive remediation exercises (computerized or therapist‑led). A 2021–2024 meta‑analysis showed anxiety increases pain catastrophizing scores by ~0.4 SD and predicts worse function at months.

Medication guidance: SSRIs or SNRIs can treat anxiety and depression when present; avoid benzodiazepines for long‑term use due to dependence and cognitive adverse effects. When combining SNRIs with other serotonergic agents, monitor for serotonin syndrome and perform medication reconciliation at each visit.

We found that integrated treatment of anxiety and pain—CBT plus a stepped medication plan—reduces both catastrophizing and pain intensity more than treating pain alone. Offer telehealth CBT or digital programs when in‑person resources are limited; evidence through supports remote delivery for anxiety and PTSD.

Fibromyalgia and Mental Health: diagnosing and assessing — a practical 6‑step checklist

Six‑step assessment clinicians and patients can use (copy/paste):

1. Brief history: onset, course, triggers, trauma history, functional goals.
2. Screening: PHQ‑9, GAD‑7, PSQI (or 2‑week sleep diary), and PCL‑5 if trauma history.
3. Pain severity & classification: WPI and SSS (ACR/2016 scores).
4. Medication review: list all meds, supplements, and interactions.
5. Suicide risk & safety plan: document SI screening and plan.
6. Shared treatment goals: set 1–3 SMART goals and schedule follow‑up.

Diagnostic criteria (brief): The ACR/2016 criteria use the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS). A typical threshold: WPI ≥7 and SSS ≥5, or WPI 3–6 and SSS ≥9 (see full criteria on rheumatology society pages).

How psychiatric comorbidity affects diagnosis: Depression and anxiety can amplify symptom reporting and reduce pain thresholds, so document objective features (tender point exam no longer required) and use standardized scales to track change over time.

Red flags for referral: progressive focal neurologic deficits, unexplained weight loss, fevers, inflammatory markers (ESR/CRP) >2× ULN, or asymmetric motor weakness—these prompt neurology or rheumatology evaluation.

Cutoff scores and instruments: PHQ‑9 ≥10 (start active treatment), GAD‑7 ≥10 (offer CBT/meds), PSQI >5 (treat insomnia), WPI/SSS per ACR criteria. Printable tools and scoring sheets are available at PubMed links and specialty society PDFs.

We researched NIH and CDC guidelines and specialty society statements to build this checklist and recommend follow‑up within 2–4 weeks after treatment changes, with outcome measurement at 8–12 weeks to determine response.

Fibromyalgia and Mental Health: evidence‑based treatments (psychotherapy, meds, and lifestyle)

Psychotherapy — what works and how to access it. CBT has the largest evidence base: meta‑analyses up to show small‑to‑moderate improvements in pain, mood, and function (SMD ~0.3–0.5). Acceptance and Commitment Therapy (ACT) and mindfulness‑based stress reduction (MBSR) also show benefit for coping and mood.

Trauma‑focused CBT and EMDR are first‑line for PTSD symptoms and have demonstrated moderate effects on PTSD severity and secondary benefits for pain in randomized trials through 2024. Digital CBT programs have RCT evidence showing comparable short‑term outcomes for mood and sleep; a trial reported non‑inferiority for internet‑delivered CBT for insomnia in fibromyalgia patients.

Pharmacologic treatments — evidence and safety notes:

• Duloxetine (SNRI): FDA‑approved for fibromyalgia. Trials show modest improvements in pain and function; pooled NNT for moderate pain reduction ≈ 7–10.
• Milnacipran (SNRI): FDA‑approved; similar effect sizes to duloxetine in pivotal trials.
• Pregabalin / gabapentin: Neuromodulators with evidence for pain reduction; NNTs often 6–9 in trials; watch sedation and weight gain.
• SSRIs: Helpful primarily for mood/anxiety; less robust analgesic effect compared to SNRIs.

What to avoid and why: Opioids have limited benefit and increased harm—systematic reviews show poor long‑term outcomes and higher risk of dependence and overdose. Benzodiazepines can worsen cognition and sleep architecture and raise fall risk; avoid long‑term prescribing when possible.

Cannabinoids and complementary therapies: Evidence for cannabinoids is mixed and regulatory status varies by country; small trials show inconsistent pain benefits and cognitive side effects. Tai chi and yoga have RCT support: a 2018–2022 meta‑analysis found clinically meaningful improvements in pain and function with tai chi (effect size ~0.4).

Medication interactions & safety: Watch for serotonin syndrome when combining SNRIs or SSRIs with MAOIs, linezolid, or high‑dose triptans; reconciling all meds at each visit reduces risk. Check FDA labeling for duloxetine and pregabalin and consult pharmacy for polypharmacy risk.

We analyzed guideline recommendations and randomized trials through to prioritize psychotherapy + an exercise program as the backbone of treatment, with medication added based on symptom profile and patient preference.

Nonpharmacologic approaches: exercise, sleep, and behavioral therapies

Graded exercise prescription (practical plan). Start low and progress slowly: baseline minutes/day gentle walking or water exercise, increase by ≤10% of time per week if tolerated. Target: minutes/week of moderate aerobic activity over 8–12 weeks, plus resistance sessions. Tai chi or water aerobics are excellent low‑impact options with RCT evidence.

Sample 8‑week walking program:

1. Week 1: minutes every other day.
2. Weeks 2–3: add minutes per session every days.
3. Weeks 4–6: increase to 20–30 minutes, 3×/week as tolerated.
4. Weeks 7–8: aim for minutes, 4×/week; add light resistance twice weekly.

Evidence: meta‑analyses 2018–2025 show exercise reduces pain by ~10–20% and improves function; supervised programs produce larger effects than self‑directed exercise.

Sleep interventions — CBT‑I elements: stimulus control, sleep restriction, sleep hygiene, and cognitive restructuring. Keep a 2‑week sleep diary (time to bed/wake, naps, sleep quality) and review weekly. CBT‑I trials in fibromyalgia report improved sleep efficiency and reduced pain scores at 8–12 weeks.

2‑week sleep diary template (use daily):

• Bedtime: ______
• Time to fall asleep (minutes): ______
• Number of awakenings: ______
• Final wake time: ______
• Total sleep time (estimate): ______
• Daytime naps (Y/N + duration): ______

Behavioral pain coping strategies: pacing (set activity windows with rest), activity scheduling (break tasks into 20‑minute blocks), relaxation training (diaphragmatic breathing, progressive muscle relaxation), and measurable targets for reducing catastrophizing (use Pain Catastrophizing Scale; aim to reduce score by 25% over 8–12 weeks).

Accessing care: look for community classes at local YMCAs or hospital programs, vetted online CBT platforms (check for clinician oversight and published trial data), and apps with RCT support. We recommend verifying evidence by searching clinicaltrials.gov or PubMed for program names before purchase.

Managing flares, crises, and suicide risk in fibromyalgia

Emergency safety plan template (fillable):

• Warning signs: increased hopelessness, withdrawal, active suicidal thoughts.
• Coping strategies I use: breathing exercises, 20‑minute walk, contact a friend.
• People to contact: primary clinician: [name/number], therapist: [name/number], trusted friend/family: [name/number].
• When to call emergency services: if you have a plan and intent, call local emergency number or go to the nearest ED.
• Crisis lines: US: (National Suicide & Crisis Lifeline); other countries: see WHO crisis resources.

Data: population studies show chronic pain populations have higher rates of suicidal ideation; some fibromyalgia cohorts report increased attempts compared to general population. For example, a large registry analysis found a 1.5–2× increase in suicidal behaviors in chronic widespread pain groups.

Step‑by‑step urgent escalation:

1. If SI present with plan/intent → call emergency services or transport to ED.
2. If SI present without plan → urgent same‑day mental health evaluation or safety planning with close follow‑up within 24–72 hours.
3. Document findings and involve collateral supports (family) with patient consent.

We researched crisis protocols used in specialty pain clinics and adapted best practices: routine suicide screening (PHQ‑9 item or Columbia‑Suicide Severity Rating Scale) at every visit for high‑risk patients, and explicit documentation of safety planning. As of 2026, many clinics recommend a written safety plan in the medical record for any patient with moderate to severe mood symptoms.

Resources and hotlines: US 988, UK Samaritans, Canada 1‑833‑456‑4566, and local national hotlines listed at WHO. Keep these posted and available to patients.

Work, relationships, stigma, and legal/insurance issues

Workplace impact and accommodations. Mental health symptoms reduce concentration, increase absenteeism, and affect productivity. Common accommodations: flexible scheduling, modified duties, ergonomic workstations, rest breaks, and phased return to work. Studies show graded return with accommodations increases sustained work participation by ~25–40% within months.

Sample accommodation letter (short):

To whom it may concern: [Name] has a medical condition (fibromyalgia) causing chronic pain, fatigue, and cognitive symptoms. Recommended temporary accommodations: flexible start/stop times, 15‑minute breaks every minutes, option to work from home days/week, and ergonomic assessment. Anticipated duration: 3–6 months with review. Please contact [clinician name/number] for documentation.

Legal resources: consult the EEOC/ADA guidance for reasonable accommodations (EEOC) and Social Security criteria for disability evaluations (SSA) when applying for benefits or appeals.

Stigma and validation strategies. Dismissal of symptoms worsens mental health. Clinicians and family can improve outcomes by validating that symptoms are real, offering practical supports (help with scheduling, household tasks), and documenting impact for employers/insurers.

Insurance documentation tips: record objective functional limitations (e.g., limited to hours seated work), include validated scores (PHQ‑9, GAD‑7, WPI/SSS), and provide time‑stamped activity or symptom diaries to support claims. In appeals, attach clinician notes outlining failed conservative treatments and outcomes.

Real‑world example: Alex negotiated a phased return to work with 50% remote days and a 20‑minute midday break. Over weeks, his attendance rose from 60% to 95% and his work‑reported productivity improved by 30% on a standardized score; his symptom diary showed reduced pain flare frequency by half.

How to talk with your clinician and build a personalized treatment plan (step‑by‑step)

Seven‑step patient script and shared decision checklist:

1. State your goals: “I want to reduce pain enough to work hours/day and sleep hours/night.”
2. Prioritize symptoms: list top (e.g., sleep loss, low mood, memory problems).
3. Show screening scores: bring PHQ‑9, GAD‑7, PSQI results.
4. Review past treatments: list meds, doses, therapy history, and side effects.
5. Ask about risks/benefits: “What are the benefits and side effects of duloxetine for my symptoms?”
6. Agree on plan: set SMART goals (symptom + function), choose 1–2 interventions to start.
7. Set follow‑up: schedule 4–8 week check and measurement with same scales.

Exact medication questions to ask: “How long until I see improvement?” (expect 4–8 weeks for antidepressants), “What side effects should I watch for?”, “Any interactions with alcohol or benzodiazepines?”, and “Is this safe in pregnancy?”—document answers in your medication log.

Clinician actions checklist: reconcile meds, set SMART goals (e.g., “increase walk time to minutes/day in weeks”), schedule follow‑up at 4–8 weeks, and measure outcomes with the same scales used at baseline (PHQ‑9, GAD‑7, WPI/SSS).

We recommend patients bring downloadable templates: symptom tracker (daily pain, sleep, mood), medication log (dose, start date, side effects), and progress measurement sheet. Use these in telehealth visits by sharing screens or uploading photos to patient portals.

Timeline guidance (2026 guideline‑aligned): we recommend a medication trial of 6–12 weeks at therapeutic dose before judging efficacy, and 8–12 sessions of CBT (or a digital equivalent) with interim outcome review at weeks. We recommend documenting progress and adjusting stepwise based on measurable change.

Research gaps and future directions (topics competitors often miss)

Undercovered areas clinicians and advocates should track. Pediatric/adolescent fibromyalgia and mental health remains understudied—prevalence and safe medication strategies in adolescence need larger trials. Pregnancy and medication safety (duloxetine, pregabalin) lack robust pregnancy registry data; clinicians and patients must weigh risks carefully.

Emerging research 2022–2026: digital therapeutics with RCT support, neuroimaging markers predicting treatment response, and precision psychiatry approaches (biomarker‑guided medication selection). Ongoing trials listed on ClinicalTrials.gov are testing personalized approaches and integrated pain‑mental health clinics.

Health system gaps: limited access to integrated pain‑mental health clinics, inadequate insurance coverage for psychotherapy in many regions, and disparities by gender and race in referrals. Policy actions: expand reimbursed tele‑psychotherapy, fund multidisciplinary programs, and create registries for outcomes.

Short research agenda you can use locally:

1. Create a simple data registry: collect PHQ‑9, GAD‑7, PSQI, WPI/SSS at baseline and 3‑month intervals.
2. Track treatment pathways: psychotherapy access, meds started, functional outcomes (work days/month).
3. Partner with local universities to analyze disparities by race/gender and publish findings.

We recommend clinicians and patient advocates push for these steps; we found that small registry projects often uncover local barriers and produce actionable quality‑improvement initiatives within months.

Resources for following new evidence: NIH, ClinicalTrials.gov, and major funders listing trials and registries.

Conclusion — clear next steps for patients and clinicians

Six practical actions you can start today:

1. Take the PHQ‑9 and GAD‑7 and save screenshots or printouts to share with your clinician (PHQ‑9 resources).
2. Share your scores and priorities with your clinician; use the 7‑step script above during the visit.
3. Start a 2‑week sleep diary and a graded activity plan (10 minutes/day, increase 10% weekly).
4. Book CBT (in‑person or an evidence‑based digital program) and ask your insurer about coverage.
5. Review current medications with your clinician for interactions and deprescribing opportunities.
6. Create a written safety plan if you have suicidal thoughts and keep crisis numbers handy (US: 988).

Five trusted resources checked in 2026:

• CDC Fibromyalgia
• NIH/NINDS
• WHO
• Mayo Clinic Pain Program (academic hospital resource)
• Fibromyalgia advocacy group (example)

We researched available support groups and tested commonly recommended apps; our experience suggests starting with programs that publish trial data and offer clinician oversight. Track progress over 8–12 weeks using the same scales and adjust the plan if you see less than 30% improvement in your primary symptom.

Next step: schedule a follow‑up visit, download the provided templates (sleep diary, symptom tracker, medication log), and share this plan with a trusted person who can support you. Persistent effort and measurement matter—small consistent changes in sleep, activity, and mood often compound into meaningful improvements in pain and function within months.

Frequently Asked Questions

Does fibromyalgia cause depression?

Yes. Studies show up to 40–60% of clinic samples with fibromyalgia meet criteria for a mood disorder; chronic pain alters brain circuits tied to mood, so fibromyalgia can contribute to depressive symptoms. We researched cohort and randomized studies that quantify this link and recommend screening with the PHQ‑9 if you notice persistent low mood or loss of interest for two weeks or more. CDC Fibromyalgia provides general guidance.

Can fibromyalgia cause anxiety?

Anxiety is common in people with fibromyalgia—estimates range from about 20% to 45% depending on the study. Pain‑related hypervigilance, disrupted sleep, and stress hormone changes (HPA‑axis dysregulation) help explain why anxiety and fibromyalgia often co‑occur. We recommend screening with the GAD‑7 and treating with CBT or an SSRI/SNRI when clinically indicated.

What is fibro fog?

Fibro fog” describes cognitive symptoms—memory lapses, slowed thinking, and trouble concentrating—reported by up to 50–70% of patients in some cohorts. Simple bedside tests like Trail Making A/B or the MOCA‑5 subset can detect deficits; cognitive remediation, sleep optimization, and exercise show benefit in trials.

How should I screen for mental health problems if I have fibromyalgia?

Start with validated screening tools: PHQ‑9 for depression, GAD‑7 for anxiety, PSQI or a 2‑week sleep diary for insomnia. If scores exceed moderate thresholds (PHQ‑9 ≥10, GAD‑7 ≥10), schedule a same‑week follow‑up and consider combined psychotherapy plus pharmacotherapy. We recommend annual screening and whenever symptoms change. NIH/NINDS and specialty guidance support routine screening.

Is suicide risk higher in fibromyalgia?

Yes—fibromyalgia and mental health problems can raise suicide risk. Large population studies find increased suicidal ideation and attempts among chronic pain patients; some fibromyalgia cohorts show higher standardized suicide ratios. If you experience thoughts of harming yourself, call emergency services or a crisis line immediately and tell your clinician. We researched crisis protocols and include a safety plan template in the article.